Ocular Therapeutix Inc (NASDAQ: OCUL) has seen a decline in its stock price by -2.70 in relation to its previous close of 7.79. However, the company has experienced a -4.17% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-15 that The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
The 36-month beta value for OCUL is also noteworthy at 1.36. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for OCUL is 135.05M, and at present, short sellers hold a 8.74% of that float. The average trading volume of OCUL on April 18, 2024 was 2.08M shares.
OCUL’s Market Performance
OCUL stock saw a decrease of -4.17% in the past week, with a monthly decline of -19.70% and a quarterly a decrease of 82.65%. The volatility ratio for the week is 6.00%, and the volatility levels for the last 30 days are 5.87% for Ocular Therapeutix Inc (OCUL). The simple moving average for the last 20 days is -13.23% for OCUL stock, with a simple moving average of 54.60% for the last 200 days.
Analysts’ Opinion of OCUL
Many brokerage firms have already submitted their reports for OCUL stocks, with BofA Securities repeating the rating for OCUL by listing it as a “Buy.” The predicted price for OCUL in the upcoming period, according to BofA Securities is $15 based on the research report published on February 09, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $18. The rating they have provided for OCUL stocks is “Outperform” according to the report published on April 21st, 2023.
Berenberg gave a rating of “Buy” to OCUL, setting the target price at $15 in the report published on August 10th of the previous year.
OCUL Trading at -11.39% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.98% of loss for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 6.00%, as shares sank -21.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.13% upper at present.
During the last 5 trading sessions, OCUL fell by -4.17%, which changed the moving average for the period of 200-days by +46.90% in comparison to the 20-day moving average, which settled at $8.63. In addition, Ocular Therapeutix Inc saw 69.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from SUMMER ROAD LLC, who purchase 930,851 shares at the price of $7.52 back on Feb 26 ’24. After this action, SUMMER ROAD LLC now owns 8,591,401 shares of Ocular Therapeutix Inc, valued at $7,000,000 using the latest closing price.
Mattessich Antony C., the President and CEO of Ocular Therapeutix Inc, sale 18,338 shares at $4.95 during a trade that took place back on Jan 31 ’24, which means that Mattessich Antony C. is holding 427,943 shares at $90,773 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -1.41 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -1.49. The total capital return value is set at -0.38. Equity return is now at value -127.64, with -40.23 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -0.85. The debt to equity ratio resting at 0.84. The interest coverage ratio of the stock is -18.36.
Currently, EBITDA for the company is -79.4 million with net debt to EBITDA at 1.42. When we switch over and look at the enterprise to sales, we see a ratio of 17.39. The receivables turnover for the company is 2.23for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.66.
Conclusion
In summary, Ocular Therapeutix Inc (OCUL) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
